Toronto, Ontario--(Newsfile Corp. - January 20, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma Bright" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce it has received a follow-on order for an additional 200 Venowave VW5 units from its Texas-based distribution partner, Gen-X Med.
This latest transaction marks the expansion of the relationship between the two companies, following the successful initial integration of the Venowave system into Gen-X Med's specialized healthcare network. The units are destined for use by top-tier orthopedic surgeons, specifically targeting post-surgical recovery for specialized knee procedures-a high-growth segment in the U.S. healthcare landscape.
Rob Fia, CEO, commented:
"The speed at which Gen-X Med has returned for additional inventory speaks volumes about the clinical demand for the Venowave VW5. This second 200-unit order reinforces our belief that the market is hungry for mobile, effective, and reimbursable compression solutions. By helping surgeons reduce post-operative complications and hospital readmissions, we are not only improving patient lives but also providing a clear economic benefit to the U.S. healthcare system. We look forward to scaling this volume as Gen-X Med continues to educate their expansive doctor network."
Beau Wood, President of Gen-X Med, commented:
"Our initial rollout confirmed what we suspected: patients and providers prefer the mobility and efficacy of the Venowave over traditional, tethered compression devices. Securing these additional 200 units allows us to keep pace with the growing adoption rate among our specialized knee surgeons. We are seeing a shift toward 'at-home' recovery solutions, and Venowave is the clear leader in that transition."
The Growing Compression Therapy Market
The global compression therapy market is currently experiencing significant tailwinds. According to industry data from Straits Research, the market was valued at **$4.18 billion in 2024 and is projected to reach $6.72 billion by 2033**, growing at a steady compound annual growth rate (CAGR) of 7.30%. This growth is driven by an aging population, an increase in orthopedic surgeries, and a heightened focus on preventing Deep Vein Thrombosis (DVT) and other circulatory disorders.
About the Venowave VW5
The Venowave VW5 is a compact, battery-operated peristaltic pump designed as a portable, at-home solution for the treatment of circulatory disorders. When positioned below the knee, the FDA-designated Durable Medical Equipment (DME) device generates a gentle, wave-like motion to improve blood circulation and lymphatic function. Clinically shown to enhance venous blood flow by 64% after just two minutes of use and 88% after 50 minutes, the Venowave is the only Medicare-approved reimbursable mobile mechanical compression system available in the U.S. under its HCPCS code E0683. It provides a comfortable and simple treatment solution to accelerate post-operative recovery while managing pain and swelling.
About Gen-X Med
Gen-X Med is an Arlington, Texas-based distributor committed to providing healthcare professionals with specialized, vetted products and exceptional client care. The company's portfolio includes durable medical equipment (DME) products, with a focus on sourcing and providing the most qualified products and services to meet the needs of its clients.
Visit: http://www.genxmed.net/
About Therma Bright Inc.
Therma Bright is a developer and investment partner specializing in advanced diagnostic and medical device technologies. The Company's portfolio includes innovative solutions for vascular health, respiratory diagnostics, and topical treatments. Therma Bright is listed on the TSX Venture Exchange (THRM), the OTCQB (TBRIF), and the Frankfurt Stock Exchange (JNX0).
For further information, please contact:
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com
Follow us on X:
https://x.com/Bright_Therma
FORWARD-LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as future sales of Venowave and related technology as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/280905
Source: Therma Bright Inc.
